NEWS
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
Mainz Biomed N.V. (NASDAQ: MYNZ) has announced significant improvements to its ColoAlert product, a highly efficacious at-home detection test for colorectal cancer (CRC). The enhancements include:
1. A novel DNA stabilizing buffer that accommodates varying sample volumes, reducing the need for retesting and enabling results delivery within 2-3 days.
2. Refined kit features for improved usability, including an enhanced collection device and new tube design.
These upgrades aim to enhance customer satisfaction, streamline lab operations, and maintain ColoAlert's position as a leading CRC screening solution. The improved product is now available to existing and prospective laboratory partners.
1. A novel DNA stabilizing buffer that accommodates varying sample volumes, reducing the need for retesting and enabling results delivery within 2-3 days.
2. Refined kit features for improved usability, including an enhanced collection device and new tube design.
These upgrades aim to enhance customer satisfaction, streamline lab operations, and maintain ColoAlert's position as a leading CRC screening solution. The improved product is now available to existing and prospective laboratory partners.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1692Followers
93Following
13KVisitors
Follow